(Q40576877)

English

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma

scientific article published on May 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

21 September 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Christopher W Ryan

1

1 reference

Europe PubMed Central

21 September 2017

Nicholas J Vogelzang

2

1 reference

Europe PubMed Central

21 September 2017

Walter M Stadler

3

1 reference

Europe PubMed Central

21 September 2017

language of work or name

0 references

publication date

1 May 2002

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

94

1 reference

Europe PubMed Central

21 September 2017

2602-2609

1 reference

Europe PubMed Central

21 September 2017

10

1 reference

Europe PubMed Central

21 September 2017

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

21 January 2018

A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

21 January 2018

Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

21 January 2018

Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

21 January 2018

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

21 January 2018

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

21 January 2018

Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

21 January 2018

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

7 January 2021

based on heuristic

inferred from DOI database lookup

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10528

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10528

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40576877&oldid=1903217159"